Efficacy and safety of human intravenous immunoglobulin 5% (Ig VENA) in pediatric patients affected by primary immunodeficiency

Patients affected by primary immunodeficiencies are characterized for high susceptibility for severe infections. Our data demonstrate Kedrion 5% intravenous immunoglobulin G (IVIg) treatment effective and safe as replacement therapy for children and adolescents affected by primary immunodeficiency....

Descripción completa

Detalles Bibliográficos
Autores principales: Ricci, Silvia, Lippi, Francesca, Canessa, Clementina, Guarnieri, Chiara, Macchia, Roberta, Azzari, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493272/
https://www.ncbi.nlm.nih.gov/pubmed/32924667
http://dx.doi.org/10.1177/2058738420943006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493272/
https://www.ncbi.nlm.nih.gov/pubmed/32924667
http://dx.doi.org/10.1177/2058738420943006

Ejemplares similares